Skorpios Trust Reduces Stock Position in Stoke Therapeutics, Inc. $STOK

Skorpios Trust lessened its position in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 52.9% during the second quarter, Holdings Channel reports. The institutional investor owned 3,256,181 shares of the company’s stock after selling 3,650,000 shares during the quarter. Stoke Therapeutics makes up approximately 99.6% of Skorpios Trust’s investment portfolio, making the stock its largest position. Skorpios Trust owned 0.06% of Stoke Therapeutics worth $36,958,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP grew its holdings in shares of Stoke Therapeutics by 0.9% in the 1st quarter. Wellington Management Group LLP now owns 135,960 shares of the company’s stock worth $904,000 after acquiring an additional 1,148 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Stoke Therapeutics by 5.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after acquiring an additional 1,149 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock worth $36,000 after acquiring an additional 5,084 shares during the last quarter. KLP Kapitalforvaltning AS grew its holdings in shares of Stoke Therapeutics by 131.6% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 13,200 shares of the company’s stock worth $150,000 after acquiring an additional 7,500 shares during the last quarter. Finally, MPM Bioimpact LLC grew its holdings in shares of Stoke Therapeutics by 1.2% during the first quarter. MPM Bioimpact LLC now owns 693,988 shares of the company’s stock valued at $4,615,000 after buying an additional 8,162 shares in the last quarter.

Stoke Therapeutics Stock Performance

STOK opened at $32.52 on Thursday. The company has a market cap of $1.78 billion, a PE ratio of 38.26 and a beta of 1.24. The stock has a 50-day moving average of $24.20 and a 200-day moving average of $15.32. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%.The business had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $31.51 million. On average, research analysts predict that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on STOK shares. Chardan Capital reiterated a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, August 13th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Stoke Therapeutics in a report on Wednesday, October 8th. Jefferies Financial Group assumed coverage on Stoke Therapeutics in a research report on Friday, July 18th. They set a “buy” rating and a $30.00 price objective for the company. Wedbush upped their target price on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 13th. Finally, BTIG Research upped their target price on Stoke Therapeutics from $28.00 to $39.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $30.83.

Insider Buying and Selling

In related news, Director Edward M. Md Kaye sold 45,996 shares of the business’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $20.13, for a total transaction of $925,899.48. Following the completion of the transaction, the director owned 91,585 shares of the company’s stock, valued at approximately $1,843,606.05. The trade was a 33.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Jonathan Allan sold 14,922 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $20.14, for a total value of $300,529.08. Following the transaction, the general counsel directly owned 18,176 shares of the company’s stock, valued at $366,064.64. This represents a 45.08% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 185,180 shares of company stock valued at $4,129,406. Insiders own 9.50% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.